Crohn’s disease is a type of inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, which can/may lead to severe diarrhea, abdominal pain, weight loss, fatigue, and malnutrition. There’s currently no cure for Crohn’s disease, but treatment can help control or reduce the symptoms and help stop them coming back. Sometimes surgery may be needed. There no single treatment that works for everyone, but many treatments can provide a lot of relief, and in some cases, even long-term remission. Treatment for Crohn’s disease may involve medication, nutritional supplements, and surgery. The aim is to control inflammation, relieve symptoms, resolve nutritional problems, and reduce the occurrence of flares.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/1237
Frequent approvals and launches of novel products by market players are expected to augment the growth of the global Crohn’s disease treatment market. With the increasing prevalence of Crohn’s disease, the demand for Crohn’s disease treatment is also increasing with a rapid pace. For instance, in March 2020, Takeda Pharmaceutical announced that China’s National Medical Products Administration (NMPA) has approved gut-selective biologic Entyvio (vedolizumab) for adult patients with moderate to severe Crohn’s disease or active ulcerative colitis.
Moreover, increase in research and development activities and increasing number of clinical trials are expected to boost growth of the global Crohn’s disease treatment market. For instance, in January 2021, Crohn’s & Colitis Foundation and LifeArc teamed up to encourage research that could help to advance a promising new prognostic test closer to the clinic. The goal is to help deliver precision medicine for children with Crohn’s disease, improving the treatment and quality of life for people living with these serious long-term conditions.
North America is expected to witness robust growth in the global Crohn’s disease treatment market owing to the increasing research and development in this region. For instance, in May 2021, the data from Eli Lilly & Company’s Phase 2 study showed that mirikizumab may help improve fatigue in patients with moderately to severely active Crohn’s disease, reinforcing the importance of further study into mirikizumab as a potential treatment for those living with this disease (Crohn’s disease).
The outbreak of COVID-19 has had a severe impact on almost all industry verticals, including the private healthcare sector, due to disruption in the supply chain of the healthcare industry. The pandemic is putting unprecedented pressures on healthcare systems worldwide.
For instance, according to an article published in 2020 by the British medical journal (BMJ), COVID-19 had significantly impacted the pediatric endoscopy for IBD in the United Kingdom. Only two sites (10%) reported access to routine endoscopy for patients with IBD during April. Moreover, over 50% of children and young people presenting with a suspected diagnosis of IBD were diagnosed without a histological diagnosis due to restrictions placed on endoscopy at over 90% of centers across the U.K.
Key players active in the global Crohn’s disease treatment market are AstraZeneca, Novartis AG, Amgen Inc., Mylan N.V., Sanofi, Eli Lilly and Company, AbbVie Inc., Pfizer Inc., Janssen Biotech, Inc., Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, and Bristol-Myers Squibb Company, among others.
Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1237
In June 2022, Sandoz announced that the European Medicines Agency (EMA) has accepted an application for high concentration formulation 100mg/mL of biosimilar Hyrimoz for regulatory review. The application includes all indications covered by the reference medicine, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, ulcerative colitis, and uveitis.
In February 2021, Celltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma (CT-P17), an adalimumab biosimilar, intended for the treatment of multiple chronic inflammatory diseases.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Crohn’s Disease Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Crohn’s Disease Treatment Industry Impact
Chapter 2 Global Crohn’s Disease Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Crohn’s Disease Treatment (Volume and Value) by Type
2.3 Global Crohn’s Disease Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Crohn’s Disease Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Crohn’s Disease Treatment Market Analysis
Chapter 6 East Asia Crohn’s Disease Treatment Market Analysis
Chapter 7 Europe Crohn’s Disease Treatment Market Analysis
Chapter 8 South Asia Crohn’s Disease Treatment Market Analysis
Chapter 9 Southeast Asia Crohn’s Disease Treatment Market Analysis
Chapter 10 Middle East Crohn’s Disease Treatment Market Analysis
Chapter 11 Africa Crohn’s Disease Treatment Market Analysis
Chapter 12 Oceania Crohn’s Disease Treatment Market Analysis
Chapter 13 South America Crohn’s Disease Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Crohn’s Disease Treatment Business
Chapter 15 Global Crohn’s Disease Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/1237
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027